Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study is a prospective, multicenter, randomized, open controlled clinical trial aimed at evaluating the effectiveness and safety of serplulimab plus chemoradiotherapy in FIGO 2018 stage III or IVA cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma patients who have not received prior treatment.
Epistemonikos ID: fd3f0888f043f9cbbc1fe318fd9709617ec60ea4
First added on: May 22, 2024